Join us for an engaging panel discussion where leading industry experts will explore how AI is transforming everything from drug discovery to personalized medicine. Discover the most exciting advancements and potential roadblocks on the path to integrating AI into life sciences. We’ll explore pressing topics ranging from data privacy and inclusivity to the implications of human-like AI, the future of VC funding for AI-driven startups, and the evolving role of AI over the next decade.

Disclaimer: This event may be recorded, and your image and/or voice may be included in that recording. If you are uncomfortable, please be sure to turn off your webcam.  

Speaker Bios

Catherine Blanchette, Vice President and Head of Digital Strategic Partnerships at Sanofi

Catherine is a global health technology executive with over 20 years of experience driving digitally disruptive strategy, M&A, partnerships, go-to-market planning, and execution across tech, healthcare, and life sciences. She loves "connecting the dots" across industries to find new and more effective ways to drive value for the industry and, most importantly, patients. With a proven ability to solve complex business issues and build talented, high-performing teams, she aims to drive transformative and exponential growth across the entire value chain. Catherine received her MBA from Boston College's Carroll School of Management.

Julie Huxley-Jones, VP of Research and Manufacturing Technology at Vertex Pharmaceuticals

Julie is a serial innovator, cultivating creativity to transform health outcomes. For over 20 years, she has brought passion, dynamism, and innovation to healthcare, combining depth in technology, data, and AI with strategic, operational, and fiscal breadth and R&D expertise to discover, develop, and manufacture life-altering treatments. She is a value-driven leader with purpose, people, and patients at heart. She is a World 50 Women Executive member for top global talent, a CHIEF UK founding member for executives, and a GSK representative on multiple industry fora, including PRISME leaders in R&D technology. She received her PhD from the University of Manchester.

Milind Kamkolkar, Venture Partner at RA Capital Management

Milind is a seasoned executive with 20+ years of experience across Fortune 500 enterprises, startups, and management consulting. He has deep experience in strategy and innovation, operations, and P&L growth. His focus is on equitable access to health, medicine, education, and nutrition. He advocates for global sustainability and neurodiversity. He volunteers for an AI-driven neuroscience company, OccamzRazor.

Arturo Morales, Managing Director and Head of Technology and Data Science at XponentL Data

With over 20 years of experience in data science and technology, Dr. Morales is a passionate and visionary leader who enables pharma and biotech organizations to leverage data and analytics for drug discovery and digital health. As the Managing Director and Head of Technology and Data Science at XponentL Data, he oversees the delivery of innovative and scalable data solutions that address the complex challenges and opportunities in life sciences and other industries. Dr. Morales has successfully led high-performing teams across multiple business units and domains and created and deployed data products that enhanced research, clinical, operational, and business outcomes. His mission is to empower data-driven decision-making and innovation that improve human health and life in general. Dr. Morales received his PhD at MIT, and he volunteers for the New England Rugby Referee Society.


Stephanie Oestreich, Managing Director of the Investment Fund of the MMRF, Moderator

Stephanie is Managing Director of the Investment Fund of the MMRF (Multiple Myeloma Research Foundation) and serves on the boards of the German American Business Council in Boston and the Harvard Kennedy School’s Women’s Network and is the chair of the McCloy Alumni Association. She is also on the faculty of MIT, a member of the Launchpad Venture Group, an advisor at grIP Venture Studio, to Biognosys (a Bruker company), Invitris, CART company CelineTx, Investment Fund Nekonal, and to the drug development and investment company OrangeGrove Bio and a member of the W20 Entrepreneurship task force, the official engagement group of the G20. Previously she was Chief Business Officer at Galecto (NASDAQ:GLTO), Vice President at cell therapy company Mnemo Therapeutics, a Venture Partner at RA Capital and Executive Vice President at Evotec (NASDAQ:EVO) where she built its North American investment arm and started an incubator with Samsara BioCapital. She also worked as International Business Leader at F. Hoffmann-La Roche Ltd. (ROG.SW), and for Novartis (NYSE:NVS) in Business Development and in Commercial. Stephanie conducted the research for her PhD in biochemistry in the lab of a Nobel Prize winner at Harvard Medical School and obtained an MPA from the Harvard Kennedy School. As a semi-professional violinist, she performs with Philharmonic orchestras in Carnegie Hall and other international venues and conducts workshops with live orchestras, demonstrating the similarities between teams and leadership in music and management.

Diane Wuest, Vice President, AI & Analytics Products at Genmab, Moderator

Dr. Diane Wuest is a passionate global executive leading AI programs and digital transformation at the interface of healthcare and technology. She has built deep knowledge in biopharma and high-tech over the past 20 years to accelerate operations and deploy emergent solutions of data and digital to solve healthcare’s most difficult challenges. Diane has designed and implemented technology strategies across AI/ML, data, operations, and digital health to optimize business investments, enterprise platform capabilities, operating models, and resourcing. Currently the VP of AI & Analytics Products at Genmab, she professionalizes AI approaches into stable products and capabilities deployed within all business functions to optimize Genmab’s promise for patients. Prior to Genmab, Diane was VP of Digital R&D at Sanofi, reporting to the Chief Digital Officer, and partnered with the R&D Global Function, where she led the strategic digital transformation of R&D’s engine via technology innovation to accelerate operations and disrupt the way drugs are discovered and developed. Diane also led precision medicine programs at Aitia, a mid-size machine learning startup, where she led strategy and deployed causal inference ML/AI programs with pharma, disease foundations, providers, and technology companies to elucidate disease mechanisms, advance drug discovery and clinical development, and improve patient care. At the start of her career, Diane worked for Genentech in R&D, and her graduate work focused on building a model system for Alzheimer’s disease. Diane received her BS and PhD in chemical & biomolecular engineering from Cornell University and the University of Delaware, respectively.

Pricing Information

• Members/Guests: Free
• Non-Members*: $10

*Not a Member? Click here to learn about the benefits of a WIB Membership — access to our video library, mentorship groups, and more. 

Please read WIB's Code of Conduct and Refund Policy.

Note: The Zoom meeting link will be sent along with a confirmation email after registration has been completed. 

Special Pricing for Guests

Members can register guests at member pricing.